Cytek Biosciences Q4 revenue rises 8%

Cytek Biosciences

26/02/2026 21:54

Overview

Cell analysis solutions firm's Q4 revenue grew 8% yr/yr, highest quarterly revenue achieved

Net loss in Q4 primarily due to non-cash valuation allowance against deferred tax assets

Outlook

Cytek Biosciences projects 2026 revenue between $205 mln and $212 mln

Result Drivers

FSP INSTRUMENT SALES - Strong momentum in FSP instrument sales across major markets contributed to Q4 revenue growth

RECURRING REVENUE GROWTH - Recurring revenue, including service and reagent sales, grew 21% in 2025, reaching 34% of total revenue

Company press release: ID:nGNXCtF61

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
-$44.08 mln
Q4 Adjusted EBITDA
$4.49 mln
Q4 Adjusted Gross Margin
53.00%
Q4 Pretax Profit
-$4.03 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

Wall Street's median 12-month price target for Cytek Biosciences Inc is $6.00, about 37.3% above its February 25 closing price of $4.37

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)